Skip to content

Shares (Basic) at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
192.5M+0.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
100.6M+4.5%
XER
Xeris Biopharma Holdings, Inc.XERS
170.5M+11.9%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
27.3M+1.5%
Theravance Biopharma logo
Theravance BiopharmaTBPH
51.3M+3.2%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
179.8M+6.3%

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$773.23M+56.4%
Enterprise value$678.78M+30.8%
P/E6.2×
P/S6.3×-5.9×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s shares (basic)?
Zevra Therapeutics, Inc. (ZVRA) reported shares (basic) of 58.4M in Q1 2026.
How has Zevra Therapeutics, Inc.'s shares (basic) changed year-over-year?
Zevra Therapeutics, Inc.'s shares (basic) increased by 8.0% year-over-year, from 54.1M to 58.4M.
What is the long-term trend for Zevra Therapeutics, Inc.'s shares (basic)?
Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s shares (basic) has grown at a 18.1% compound annual growth rate (CAGR), from 113.3M to 220.1M.
What does shares (basic) mean?
The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.